Our team

Dr. Schwarm vast experience in the pharmaceutical industry dated back more than 3 decades.  Throughout his career, he held several senior managerial positions and a great variety of functions in many locations around the world.

Dr. Schwarm left Alfred E. Tiefenbacher GmbH, Germany in 2016 to continue his activities as an independent consultant in the Pharma and Healthcare industries.  He is also a Board Member of Auxilto Healthcare GmbH, Germany.  Besides, he is lecturing at Goethe University in Frankfurt, Germany, (Pharma MBA).

During his 6 years in Alfred E. Tiefenbacher GmbH & Co. KG., Germany, as Joint Managing Director he was responsible for Development, Regulatory Affairs, Technology Transfer, and Quality as well as the Chairman of AET Laboratories Ltd., India.

The career in STADA Arzneimittel AG, Germany is well over 16 years in various Senior and Corporate Management level for Technical Operations and Supply Chain.  At the Corporate Management level, the departments reporting to him are the Quality Assurance, Production, Procurements and Logistics.

Prior to STADA Arzneimittel AG, Dr. Schwarm spent 6 years in American Home Product (now Pfizer), heading the Quality Control and Product Development Departments.

Dr. Schwarm is a member of the German Medicines Manufacturers’ Association, Committee on Pharmaceutical Technology at Germany Medicines Manufacturers’ Association, Goethe University Business School, German Association of Food Chemistry, Association of German Chemists, and the German Association for Biological Chemistry.

Dr. Schwarm received his degree in Food Chemistry and Pharmacy at University of Aachen and Munich.  Subsequently promoted to Doctor’s Degree of Natural Science at University of Erlangen, Germany.  He is also degree holder of Pharmacist for Pharmaceutical Analysis, Pharmacist for Pharmaceutical Technology, and Certificated Food Chemist.

Mr. Tilman Ronneper is a German lawyer who is practicing as a Managing Director of a Commercial Law firm since 2013. His special expertise lies in the support of long-winded and difficult cases, which demand his abilities to act entrepreneurially beyond the legal specialist level.

Besides serving his clients in Germany, Mr. Ronneper serves companies and international corporations in many other parts of the world.
He is also the Managing Directors / Directors of several companies with pharmaceutical background, being appointed as a result of his successful work.

Prior to the partnership in his present law firm, Mr. Ronneper began his career as an Attorney at law in a commercial law firm in Germany.

Mr. Kloeter’s vast experience and success in the pharmaceutical industry dated back as far as 1986. Throughout his career, he held various senior positions with different leadership functions particularly in the areas of Quality Management, Patients Safety and Logistics.

From 1986 till 2006, Mr. Kloeter had been working in Rodler Arzneimittel/Rorer/Sanofi, Germany, Pharma Atmos/Beecham/GSK, Germany, Weimer Pharma, Germany, and Hennig Arzneimittel, Germany responsible for Quality, Technology, Production, Development, Regulatory, Logistics, Sales Business Administration, and Business Transformation.

Mr. Kloeter reached a new height in his career at STADA Arzneimittel AG, joining as the Head of Quality Assurance Department and gradually taking on more responsibilities to become an Executive Vice President Global Quality, an extension of the STADA’s Executive Board.

As an Executive Vice President, Mr. Kloeter carried the responsibilities of global technological investment, technology transfer of production, cost and human resources planning, portfolio strategies and management, streamlining of efficiency and cost reduction programs, due diligence and etc.
Most of the production sites’ QA/QC departments in STADA were reporting directly to Mr.Kloeter. Due to this, Mr. Kloeter had been the Directors in many of the STADA’s subsidiaries, such as in Vietnam, Thailand, Hong Kong, India, China, UAE, South Africa, Romania, Serbia, Austria, and Germany.

Mr. Kloeter left STADA in 2019 to become an independent consultant for the pharmaceutical industry. He is an Elected Member of Federation of German Drugmaker for “Pharmaceutical Technology Committee”. Mr. Kloeter received his Degrees in Chemical Engineering, Business Administration, Degree of Engineer “Dipl. Ingenieur” in 1983.

Mr. Retzlaff long and successful career in the pharmaceutical industry dated back to 1976 when he kicked start his career in ASTRA GmbH, Germany. He was quickly promoted to be the Regional Field Staff Director before joining Abbot in 1981 in a similar capacity.

After leaving Abbot in 1986, Mr. Retzlaff became the Head of Marketing and Distribution at STADApharm GmbH, the subsidiary in the STADA group for the Generics business. In 1992 he was appointed as the Managing Director with additional roles as Deputy Member of the Board for Marketing, Distribution, Approvals, Medical Science, and International Subsidiaries of the STADA group.

In 1993, Mr. Retzlaff was appointed as the CEO / Chairman of the Executive Board of Stada Arzneimittel AG, a period spanning over 23 years until his retirement in 2016. During his term as CEO of STADA, we witnessed the fast expansion of STADA both domestically and internationally as well as diversification into other sectors of the pharmaceutical industry.

From a practically unknown company, STADA had risen rapidly under the leadership of Mr. Retzlaff to be among the top 3 generics player in Germany. Besides the success in the generics sector, the decision from Mr. Retzlaff to invest in OTC products enable STADA to be a strong contender in this sector as well. Products like Grippostad, Ladival, & others had been the leading brands in the German markets. His decision to acquire Cellpharm GmbH enabled STADA to participate in the Oncology and Biosimilar fields.

From a predominantly a German based company with heavy dependent on local sales, Mr. Retzlaff had successful transformed STADA into a multinational company with full coverage of the EU markets, most countries in Eastern Europe, the Middle East, countries along the Asian Pacific Region as well as Australia. The success in this expansion program is evidenced by the results achieved. The sales revenues generated from overseas markets had already surpassed the sales in Germany shortly after he became the CEO of STADA.

Other than the organic growth, decisions from Mr. Retzlaff to acquisition or formation of Joint Venture further fueled the growth of the international arena. Most noticeably, the acquisition in Russia and the Joint Ventures formed in Vietnam have achieved great successes under his guidance.